Cargando…

Pregnancy Outcome after Exposure to Migalastat for Fabry Disease: A Clinical Report

Our patient was a 37-year-old woman with Fabry disease (GLA p.R112H) with a medical history of recurrent headache, nausea, vomiting, vertigo, and tobacco use (20 cigarettes/day). Fabry disease was diagnosed in 2005 when she experienced proteinuria, preeclampsia, and hypertension (201/130 mm Hg) duri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haninger-Vacariu, Natalja, El-Hadi, Sarah, Pauler, Udo, Foretnik, Marina, Kain, Renate, Prohászka, Zoltán, Schmidt, Alice, Skuban, Nina, Barth, Jay A., Sunder-Plassmann, Gere
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6942789/ https://www.ncbi.nlm.nih.gov/pubmed/31934472 http://dx.doi.org/10.1155/2019/1030259

Ejemplares similares

Pregnancies in kidney transplant recipients with complement gene variant-mediated thrombotic microangiopathy
por: Haninger-Vacariu, Natalja, et al.
Publicado: (2020)

Successful Pregnancies During Ongoing Eculizumab Therapy in Two Patients With Complement-Mediated Thrombotic Microangiopathy
por: Haninger-Vacariu, Natalja, et al.
Publicado: (2020)

Pregnancy in Complement-Mediated Thrombotic Microangiopathy: Maternal and Neonatal Outcomes
por: Haninger-Vacariu, Natalja, et al.
Publicado: (2023)

Sex Differences in Clinical Presentation and Outcomes among Patients with Complement-Gene-Variant-Mediated Thrombotic Microangiopathy
por: Aigner, Christof, et al.
Publicado: (2020)

Eculizumab use in a tertiary care nephrology center: data from the Vienna TMA cohort
por: Aigner, Christof, et al.
Publicado: (2021)

Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study
por: Hughes, Derralynn A., et al.
Publicado: (2019)

Long-term multisystemic efficacy of migalastat on Fabry-associated clinical events, including renal, cardiac and cerebrovascular outcomes
por: Hughes, Derralynn A, et al.
Publicado: (2023)

Exclusion of pregnancy in dialysis patients: diagnostic performance of human chorionic gonadotropin
por: Haninger-Vacariu, Natalja, et al.
Publicado: (2020)

Complement-Mediated Thrombotic Microangiopathy Related to COVID-19 or SARS-CoV-2 Vaccination
por: Aigner, Christof, et al.
Publicado: (2023)

Long-Term Monitoring of Cardiac Involvement under Migalastat Treatment Using Magnetic Resonance Tomography in Fabry Disease
por: Gatterer, Constantin, et al.
Publicado: (2023)

Long-term follow-up of renal function in patients treated with migalastat for Fabry disease
por: Bichet, Daniel G., et al.
Publicado: (2021)

Migalastat: A Review in Fabry Disease
por: McCafferty, Emma H., et al.
Publicado: (2019)

The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat
por: Benjamin, Elfrida R., et al.
Publicado: (2017)

A Single Lung Transplant in a Patient with Fabry Disease: Causality or Far-Fetched? A Case Report
por: Gaggl, Martina, et al.
Publicado: (2013)

Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial
por: Schiffmann, Raphael, et al.
Publicado: (2018)

Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study
por: Germain, Dominique P., et al.
Publicado: (2019)

Assessment of plasma lyso-Gb(3) for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease
por: Bichet, Daniel G., et al.
Publicado: (2020)

Correction to: Migalastat: A Review in Fabry Disease
por: McCafferty, Emma H., et al.
Publicado: (2019)

In Vitro and In Vivo Amenability to Migalastat in Fabry Disease
por: Lenders, Malte, et al.
Publicado: (2020)

Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study
por: Hughes, Derralynn A, et al.
Publicado: (2017)

Correction: Assessment of plasma lyso-Gb(3) for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease
por: Bichet, Daniel G., et al.
Publicado: (2020)

First case of atypical haemolytic uraemic syndrome following COVID-19 vaccination with BNT162b2
por: Schmidt, Sophie H, et al.
Publicado: (2022)

Efficacy and safety of migalastat in a Japanese population: a subgroup analysis of the ATTRACT study
por: Narita, Ichiei, et al.
Publicado: (2019)

Medication adherence in Fabry patients treated with migalastat: Real world experience
por: Riccio, Eleonora, et al.
Publicado: (2023)

Screening for Fabry Disease by Urinary Globotriaosylceramide Isoforms Measurement in Patients with Left Ventricular Hypertrophy
por: Gaggl, Martina, et al.
Publicado: (2016)

Migalastat HCl Reduces Globotriaosylsphingosine (Lyso-Gb(3)) in Fabry Transgenic Mice and in the Plasma of Fabry Patients
por: Young-Gqamana, Brandy, et al.
Publicado: (2013)

Impact of enzyme replacement therapy and migalastat on left atrial strain and cardiomyopathy in patients with Fabry disease
por: Pogoda, Christian, et al.
Publicado: (2023)

Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable GLA mutations following 6 months of migalastat treatment
por: Mauer, Michael, et al.
Publicado: (2017)

The migalastat GLP-HEK assay is the gold standard for determining amenability in patients with Fabry disease
por: Schiffmann, Raphael, et al.
Publicado: (2019)

Severe nephrotic syndrome and early end-stage diabetic kidney disease in ABCC8-MODY12: A case report
por: Schmidt, Sophie H., et al.
Publicado: (2023)

Consensus recommendations for the treatment and management of patients with Fabry disease on migalastat: a modified Delphi study
por: Bichet, Daniel G., et al.
Publicado: (2023)

FABry Disease Patient-Reported Outcome-GastroIntestinal (FABPRO-GI): A new Fabry disease-specific gastrointestinal outcomes instrument
por: Shields, Alan L., et al.
Publicado: (2021)

An updated classification of thrombotic microangiopathies and treatment of complement gene variant-mediated thrombotic microangiopathy
por: Aigner, Christof, et al.
Publicado: (2019)

Response to “Oral Chaperone Therapy Migalastat for the Treatment of Fabry Disease: Potentials and Pitfalls of Real‐World Data”
por: Müntze, Jonas, et al.
Publicado: (2019)

Biomarkers for Monitoring Renal Damage Due to Fabry Disease in Patients Treated with Migalastat: A Review for Nephrologists
por: Jaurretche, Sebastián, et al.
Publicado: (2022)

Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data
por: Riccio, Eleonora, et al.
Publicado: (2020)

Migalastat Treatment in a Kidney-Transplanted Patient with Fabry Disease and N215S Mutation: The First Case Report
por: Di Stefano, Valeria, et al.
Publicado: (2021)

Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After 1 Year
por: Müntze, Jonas, et al.
Publicado: (2019)

Fabry Disease: Switch from Enzyme Replacement Therapy to Oral Chaperone Migalastat: What Do We Know Today?
por: Perretta, Fernando, et al.
Publicado: (2023)

Neuroradiological differentiation of white matter lesions in patients with multiple sclerosis and Fabry disease
por: Rath, Jakob, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_f7gd5hlitp43dhl4b46fll4c2l